CMS Final Rule Prohibits Federal Medicaid and CHIP Funding for 'Sex-Rejecting Procedures' for Minors

What this means for your practice

This final rule represents a significant federal policy shift impacting healthcare providers, especially those offering services to pediatric and adolescent populations, including gender-affirming care. Practices that bill Medicaid or CHIP for 'sex-rejecting procedures' for minors, as defined by CMS, will no longer be able to claim federal financial participation for such services. The six-month grace period for existing cross-sex hormone therapy prescriptions offers a brief window for practices and patients to adjust, but does not alter the fundamental prohibition moving forward. Healthcare operators, including telehealth brands, pediatric practices, and mental health providers, must review their billing practices and service offerings to ensure compliance with these new federal restrictions and the corresponding updates to state Medicaid and CHIP plans. Non-compliance could result in denied claims and potential recoupment actions, emphasizing the critical need for immediate operational and financial adjustments.

Washington D.C. — The Centers for Medicare & Medicaid Services (CMS), an agency within the Department of Health and Human Services (HHS), has issued a final rule to restrict federal funding for certain medical procedures under the Medicaid and Children's Health Insurance Program (CHIP). Effective October 13, 2026, this regulation prohibits the use of federal dollars to fund what it terms 'sex-rejecting procedures' for individuals under specific age thresholds.

Key Provisions of the Final Rule

This final rule, identified as CMS-2451-F with RIN 0938-AV73, introduces specific requirements for state Medicaid and CHIP plans. The core mandates are as follows:

• Medicaid Program: A State Medicaid plan must now explicitly provide that the Medicaid agency will not make payments under the plan for 'sex-rejecting procedures' furnished to children under 18 years of age. Consequently, the use of Federal Medicaid dollars to fund such procedures for individuals under 18 is prohibited.
• Children's Health Insurance Program (CHIP): Similarly, a separate State CHIP plan must provide that the CHIP agency will not make payments under the plan for 'sex-rejecting procedures' furnished to children under 19 years of age. The rule concurrently prohibits the use of Federal CHIP dollars to fund these procedures for individuals under 19.

Transition Period for Hormone Therapy

Recognizing ongoing treatments, the rule includes a limited transition provision. For Medicaid and CHIP beneficiaries who are actively receiving cross-sex hormone therapy, State Medicaid and CHIP agencies may continue to claim Federal Financial Participation (FFP) for those hormone therapy medications. However, this allowance is strictly limited to a period of up to six months from the effective date of this final rule, which is October 13, 2026.

Regulatory Context: Understanding Medicaid and CHIP Funding

This final rule operates within the existing framework of Title XIX and Title XXI of the Social Security Act, which authorize federal grants to states for Medicaid and CHIP programs, respectively. These programs are primarily administered by states, subject to federal oversight and approval. Each state customizes its eligibility standards, benefits packages, and payment rates, but must do so in accordance with federal statutory and regulatory requirements. If states adhere to these federal mandates, the Federal Government provides matching funds for their expenditures.

Both Medicaid and separate CHIPs require a Federally approved State plan—a comprehensive document detailing the program's nature and scope and assuring conformity with applicable federal requirements. Federal matching payments for Medicaid expenditures are calculated using the Federal Medical Assistance Percentage (FMAP) as defined in sections 1903 and 1905(b) of the Act. For CHIP, payments utilize an enhanced FMAP, established under section 2105 of the Act, which provides a higher federal matching rate up to 85 percent, as outlined in sections 2104 and 2105(b).

However, these federal matching payments are contingent upon state plans meeting applicable federal requirements set forth in section 1902 of the Act for Medicaid and section 2102 of the Act for CHIP.

Statutory Basis for the Rule

CMS grounds this final rule in existing statutory requirements for state plans. For Medicaid, section 1902(a)(19) of the Act mandates that state plans provide safeguards to ensure care and services are delivered in a manner consistent with the best interests of recipients. Furthermore, section 1902(a)(30)(A) requires state plans to include methods and procedures for payment that assure consistency with quality of care. The CHIP statutory requirements under section 2101 also apply to this final rule.

Implications for Healthcare Providers

The implementation of this final rule on October 13, 2026, requires healthcare businesses, including telehealth platforms, pediatric clinics, and other providers serving minors, to promptly assess their compliance strategies. Providers should review their service lines, particularly those pertaining to gender-affirming care for individuals under the specified age limits, to ensure that future billing practices align with these federal prohibitions regarding Medicaid and CHIP funding. Understanding the limited grace period for existing cross-sex hormone therapy is also crucial for patient care continuity and billing accuracy during the transition. Providers should stay informed of any further guidance issued by CMS or state Medicaid and CHIP agencies that may clarify the scope or implementation of this regulation.

Key Facts

| Detail | Value | |---|---| | Effective Date | October 13, 2026 | | Agencies | Centers for Medicare & Medicaid Services (CMS), Department of Health and Human Services (HHS) | | Affected Programs | Medicaid and Children's Health Insurance Program (CHIP) | | Medicaid Age Limit | Under 18 years old for 'sex-rejecting procedures' | | CHIP Age Limit | Under 19 years old for 'sex-rejecting procedures' | | Transition Period | Up to 6 months from effective date for beneficiaries actively receiving cross-sex hormone therapy medications |

Frequently Asked Questions

What specifically does this new CMS rule prohibit regarding federal funding?

This rule prohibits the use of federal Medicaid dollars to fund 'sex-rejecting procedures' for individuals under 18 years old, and federal CHIP dollars to fund these procedures for individuals under 19 years old.

Are there any exceptions for children currently undergoing related treatments?

Yes, for Medicaid and CHIP beneficiaries actively receiving cross-sex hormone therapy, State Medicaid and CHIP agencies may continue to claim Federal Financial Participation for those hormone therapy medications for a period of up to six months from the effective date of this final rule.

When does this new regulation take effect?

These regulations are effective on October 13, 2026.

Which government agencies issued this final rule?

This final rule was issued by the Centers for Medicare & Medicaid Services (CMS) within the Department of Health and Human Services (HHS).

What specific federal programs are impacted by this rule?

This rule impacts the federal funding mechanisms for both the Medicaid program (Title XIX of the Social Security Act) and the Children's Health Insurance Program (CHIP, Title XXI of the Social Security Act).

Source: CMS — Rule: Medicaid Program; Prohibition on Federal Medicaid and Children's Health Insurance Program Funding for Sex-Rejecting Procedures Furnished to Children · 2026-08-13